Brief: Elevation Oncology Announces Promising Initial Data From Phase 1 Clinical Trial Evaluating EO-3021 In Patients With Advanced Unresectable Or Metastatic Solid Tumors Likely To Express Claudin 18.2

Elevation Oncology

06/08/2024 12:59

Aug 6 (Reuters) - Elevation Oncology Inc  ELEV.O :
    * ELEVATION ONCOLOGY ANNOUNCES PROMISING INITIAL DATA FROM
PHASE 1
CLINICAL TRIAL EVALUATING EO-3021 IN PATIENTS WITH ADVANCED
UNRESECTABLE OR METASTATIC SOLID TUMORS LIKELY TO EXPRESS
CLAUDIN 18.2
    * ELEVATION ONCOLOGY INC - EO-3021 DEMONSTRATES
DIFFERENTIATED
SAFETY PROFILE
    * ELEVATION ONCOLOGY INC - EXPECT TO INITIATE DOSING IN
COMBINATION PORTION OF PHASE 1 TRIAL BY YEAR-END 2024
    * ELEVATION ONCOLOGY INC - ADVANCING INTO DOSE EXPANSION
PORTION
OF PHASE 1 TRIAL; ADDITIONAL MONOTHERAPY DATA EXPECTED IN 1H
2025

Source text for Eikon:  ID:nPnbwFSdya 
Further company coverage:  ELEV.O 

 ((Reuters.Briefs@thomsonreuters.com;))